Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2008:328–335. doi: 10.1007/978-4-431-78847-8_23

Role of Fibrinolysis in the Nasal System

Takayuki Sejima 7, Yoichi Sakata 8
Editors: Kenzo Tanaka1, Earl W Davie2, Yasuo Ikeda3, Sadaaki Iwanaga4, Hidehiko Saito5, Katsuo Sueishi6
PMCID: PMC7121017

Abstract

In this chapter, we show the presence of tissue-type plasminogen activator (t-PA), urokinase-type plasminogen activator (u-PA), and plasminogen activator inhibitor-1 (PAI-1) in nasal mucosa. It is suggested that t-PA synthesized in mucous cells is promptly secreted and modifies the watery nasal discharge in allergic rhinitis and that u-PA activity may help with the passage of large amounts of rhinorrhea by reducing its viscosity. Furthermore, we clarify the relation between fibrinolytic components and the pathology of allergy, particularly during the development of nasal allergy and nasal tissue changes. Wild-type (WT) mice can develop nasal allergy for ovalbumin (OVA) sensitization, but PAI-1-deficient mice (PAI-1-/-) cannot. The production of specific immunoglobulins IgG1 and IgE in the serum and production of interleukins IL-4 and IL-5 in splenocyte culture supernatant increased significantly in WT-OVA mice. In PAI-1-/- mice, these reactions were absent, and specific IgG2a in serum and interferon-γ in splenocyte culture medium increased significantly. Histopathologically, there was marked goblet cell hyperplasia and eosinophil infiltration into the nasal mucosa in WT-OVA mice, but these were absent in PAI-1-/- mice. These results indicate that the immune response in WT-OVA mice can be classified as a dominant Th2 response, which would promote collagen deposition. In contrast, the Th2 response in PAI-1-/- mice was down-regulated and the immune response shifted from Th2-dominant reaction to a Th1-dominant one. Taken together, these findings suggest that PAI-1 plays an important role not only in thrombolysis but also in the immune response.

Key words: PAI-1, t-PA, u-PA, Nasal allergy, Transgenic/knockout mice

References

  • 1.Liu Y.X., Peng X.R., Ny T. Tissue-specific and time-coordinated hormone regulation of plasminogen-activator-inhibitor type 1 and tissue-type plasminogen activator in the rat ovary during gonadotropin-induced ovulation. Eur J Biochem. 1991;195:549–555. doi: 10.1111/j.1432-1033.1991.tb15736.x. [DOI] [PubMed] [Google Scholar]
  • 2.Schneiderman J., Bordin G.M., Engelberg I., et al. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. J Clin Invest. 1995;96:639–645. doi: 10.1172/JCI118079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Bugge T.H., Kombrinck K.W., Flick M.J., et al. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell. 1996;87:709–719. doi: 10.1016/S0092-8674(00)81390-2. [DOI] [PubMed] [Google Scholar]
  • 4.Carmeliet P., Moons L., Pioplis V., et al. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest. 1997;99:200–208. doi: 10.1172/JCI119148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Oh C.K., Ariue B., Alban R.F., et al. PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochem Biophys Res Commun. 2002;294:1155–1160. doi: 10.1016/S0006-291X(02)00577-6. [DOI] [PubMed] [Google Scholar]
  • 6.Gyetko M.R., Sud S., Chen G.H., et al. Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection. J Immunol. 2002;168:801–809. doi: 10.4049/jimmunol.168.2.801. [DOI] [PubMed] [Google Scholar]
  • 7.Gyetko M.R., Sud S., Chensue S.W. Urokinase-deficient mice fail to generate a type 2 immune response following schistosomal antigen challenge. Infect Immun. 2004;72:461–467. doi: 10.1128/IAI.72.1.461-467.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Sejima T., Madoiwa S., Mimuro J., et al. Expression profiles of fibrinolytic components in nasal mucosa. Histochem Cell Biol. 2004;122:61–73. doi: 10.1007/s00418-004-0664-2. [DOI] [PubMed] [Google Scholar]
  • 9.Larsen K., Maat M.P.M., Jespersen J. Plasminogen activators in human nasal polyps and mucosa. Rhinology. 1997;35:175–177. [PubMed] [Google Scholar]
  • 10.Åkerlund A., Greiff L., Andersson M., et al. Mucosal exudation of fibrinogen in coronavirus-induced common colds. Acta Otolaryngol. 1993;113:642–648. doi: 10.3109/00016489309135878. [DOI] [PubMed] [Google Scholar]
  • 11.Sadwey M., Loskutoff D.J. Regulation murine plasminogen activator inhibitor 1 gene expression in vivo: tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J Clin Invest. 1991;88:1346–1353. doi: 10.1172/JCI115440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Jensen P.J., Rodeck U. Autocrine/paracrine regulation of keratinocyte urokinase plasminogen activator through the TGF-α/EGF receptor. J Cell Physiol. 1993;155:133–139. doi: 10.1002/jcp.1041550214. [DOI] [PubMed] [Google Scholar]
  • 13.Holgate S.T. Airway remodeling. Eur Respir Rev. 1998;8:1007–1011. [Google Scholar]
  • 14.Bousquet J., Jeffery P.K., Busse W.B., et al. Asthma: from bronchoconstriction to airway remodeling. Am J Respir Crit Care Med. 2000;61:1720–1745. doi: 10.1164/ajrccm.161.5.9903102. [DOI] [PubMed] [Google Scholar]
  • 15.Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost. 1999;82:259–270. [PubMed] [Google Scholar]
  • 16.Sanai A., Nagata H., Konno A. Extensive interstitial collagen deposition on the basement membrane zone in allergic nasal mucosa. Acta Otolaryngol. 1999;119:473–478. doi: 10.1080/00016489950181026. [DOI] [PubMed] [Google Scholar]
  • 17.Boulet L., Laviolette M., Turcotte H., et al. Bronchial subepithelial fibrosis correlates with airway responsiveness to methacholine. Chest. 1997;112:45–52. doi: 10.1378/chest.112.1.45. [DOI] [PubMed] [Google Scholar]
  • 18.Sejima T., Madoiwa S., Mimuro J., et al. Protection of plasminogen activator inhibitor-1 deficient mice from nasal allergy. J Immunol. 2005;174:8135–8143. doi: 10.4049/jimmunol.174.12.8135. [DOI] [PubMed] [Google Scholar]
  • 19.Hattori N., Degen J.L., Sisson T.H., et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest. 2000;106:1341–1350. doi: 10.1172/JCI10531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Mosmann T.R., Cherwinski H., Bond M.W., et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136:2348–2357. [PubMed] [Google Scholar]
  • 21.Sandler N.G., Mentink-Kane M.M., Cheever A.W., et al. Global gene expression profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for Th1 and Th2 responses in tissue repair. J Immunol. 2003;171:3655–3667. doi: 10.4049/jimmunol.171.7.3655. [DOI] [PubMed] [Google Scholar]
  • 22.Del Prete G., Maggi E., Parronch P., et al. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. J Immunol. 1988;140:4193–4198. [PubMed] [Google Scholar]
  • 23.Ueda A., Chandswang N., Ovary Z. The action of interleukin-4 on antigen-specific IgG1 and IgE production by interaction in vivo primed B cells and carrier-specific cloned Th2 cells. Cell Immunol. 1990;128:31–34. doi: 10.1016/0008-8749(90)90004-B. [DOI] [PubMed] [Google Scholar]
  • 24.Lopez A.F., Sanderson C.J., Gamble J.R., et al. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med. 1988;167:219–224. doi: 10.1084/jem.167.1.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Yamaguchi Y., Hayashi Y., Sugama Y., et al. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival: IL-5 as an eosinophil chemotactic factor. J Exp Med. 1988;167:1737–1742. doi: 10.1084/jem.167.5.1737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Deng G., Curriden S.A., Hu G., et al. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol. 2001;189:23–33. doi: 10.1002/jcp.1133. [DOI] [PubMed] [Google Scholar]
  • 27.Tarui T., Andronicos N., Czekay R.P., et al. Critical role of integrin α5β1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling. J Biol Chem. 2003;278:29863–29872. doi: 10.1074/jbc.M304694200. [DOI] [PubMed] [Google Scholar]
  • 28.Dano K., Andreasen P.A., Grondahl-Hansen J., et al. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/S0065-230X(08)60028-7. [DOI] [PubMed] [Google Scholar]
  • 29.Cho S.H., Hall I.P., Wheatley M., et al. Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene in the development of asthma. J Allergy Clin Immunol. 2001;108:212–214. doi: 10.1067/mai.2001.117260. [DOI] [PubMed] [Google Scholar]
  • 30.Bucková D., Izakovicova Hollá L., Vácha J. Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population. Allergy. 2002;57:446–448. doi: 10.1034/j.1398-9995.2002.03582.x. [DOI] [PubMed] [Google Scholar]

Articles from Recent Advances in Thrombosis and Hemostasis 2008 are provided here courtesy of Nature Publishing Group

RESOURCES